[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Quanda Liu\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":47},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":5},"100618548","clinical-efficacy-of-transarterial-infusion-chemotherapy-for-unresectable-colorectal-cancer-100618548",false,"NCT07333053","Clinical Efficacy of Transarterial Infusion Chemotherapy for Unresectable Colorectal Cancer","FOLFOX-Based Transarterial Infusion Chemotherapy for Unresectable Colorectal Cancer: An Open-Label, Multicenter, Randomized, Controlled, Phase Ⅱ Trial","Inclusion Criteria:\n\n1. Age ≥ 18 years;\n2. Colorectal cancer confirmed by CT\u002FMRI and colonoscopic biopsy；\n3. Patients unfit for surgery due to poor general condition or tumor extent and location;\n4. Patients who have not received prior chemotherapy or those who have undergone prior chemotherapy but remain chemosensitive.\n5. Adequate haematological, heart, liver and renal functions are required, with the following specific criteria: white blood cell count≥4000\u002FmL, neutrophils≥1500\u002Fmm³, platelets≥100×10⁹\u002FL, haemoglobin≥10.0 g\u002FL, total bilirubin 2.0 mg\u002FdL, aspartate aminotransferase 100 IU\u002FL, alanine aminotransferase 100 IU\u002FL, serum creatinine 1.5 mg\u002FdL or creatinine clearance rate≥60 mL\u002Fmin\u002Fbody, and urine protein\u002Fcreatinine\\\u003C1.\n6. Patients have to have an expected life expectancy of ≥3months.\n7. All the subjects in this study are required to sign an informed consent form.\n\nExclusion Criteria:\n\n1. Patients with other primary malignant tumors;\n2. Patients with gastrointestinal perforation;\n3. Patients are allergic to the antitumor agents;\n4. Women who are pregnant, breastfeeding, or planning to become pregnant;\n5. Patients who receive other antitumor therapies concurrently, such as chemotherapy, targeted therapy, or radiotherapy;\n6. Patients with MSI-H\u002FdMMR CRC；\n7. Patients for whom participation in the study is deemed to be inappropriate by the doctor in charge and\u002For the investigator for any other reasons.","ALL","18 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"NA","This is a prospective, multicenter, randomized, and open-label clinical trial. It is initiated to determine the efficacy of FOLFOX-based, transarterial infusion chemotherapy (TAIC) combined with either cetuximab or bevacizumab for patients with unresectable colorectal cancer (CRC).",[26],"Unresectable Colorectal Cancer",[28,29,30,31,32,33,34],"Transarterial Infusion Chemotherapy","Bevacizumab","Cetuximab","Colorectal Cancer","FOLFOX Protocol","Unresectable","Clinical Trial","RECRUITING","2026-03-05",{"date":38,"type":39},"2026-03-06","ACTUAL",{"date":41,"type":20},"2026-03-31",{"date":43,"type":20},"2027-12-31",{"name":45,"class":46},"Quanda Liu","OTHER",""]